相关实验视频

Updated: Jun 26, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

对于耐火性一般化肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌

Jing Lin¹, Yue Li¹, Mengcui Gui¹

¹Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Therapeutic advances in neurological disorders

|May 16, 2024

概括

泰利塔西塞普作为耐受性良好的补充疗法,对于耐火性全般化肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛. 这项研究发现,在接受telitacicept的患者中,显著的临床改善和降低了普得尼松的使用.

科学领域:

免疫学免疫学免疫学
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

耐火性泛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛
一种新的B淋巴细胞刺激受体-抗体融合蛋白Telitacicept针对GMG免疫病理.

研究的目的:

追溯评估telitacicept在耐火性GMG患者中的有效性和安全性.
评估telitacicept作为GMG的潜在附加疗法.

主要方法:

一个回顾性,单中心研究包括16名耐火GMG (MGFAII-V类) 患者.
使用MGFA-PIS,MGSTI,QMG和ADL得分来测量有效性,在3个月和6个月后跟踪降低普得尼松剂量.
此外,还评估了安全概况.

主要成果:

在3个月后,75%的患者表现出临床改善 (MGFA-PIS),其中一人实现了缓解.
在6个月后,90.1%的患者持续改善,MGSTI得分和普得尼松剂量显著降低 (p<0.05).
6个月后,MG-ADL和QMG得分明显改善 (p<0.05);治疗耐受性良好,没有严重的不良事件.

结论:

泰利塔西塞普似乎是一种可行的,耐受性良好的补充疗法,用于耐火性GMG.
这项研究提供了有价值的临床证据,支持telelitacicept作为GMG的新疗法.

关键词:

这就是B型淋巴细胞.B细胞激活因子激活因子一个诱导增殖的联结体.肌痛性骨髓损伤症 (Myasthenia) 是一个耐火性一般化肌痛性骨髓炎泰利塔接收接收

更多相关视频

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Published on: March 8, 2024

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...